Pain therapies sales to exceed $49 billion in 2026, driven by new product launches
The market for pain therapies will grow at an annual rate of 1.8% over the next 15 years, surpassing $49 billion in sales in 2026, according to a new report from health care advisory firm Decision Resources.
The loss of sales due to the generic entry of blockbuster pain therapies over the next several years will be offset by the uptake of branded and emerging agents in current drug classes such as tapentadol extended release (Johnson & Johnson/Grunenthal’s Nucynta ER/Palexia SR), orally inhaled dihydroergotamine (MAP Pharmaceuticals/Allergan’s Levadex) and opioid reformulations. Market growth will be driven primarily by the launch of the first biologic pain therapies, namely Pfizer’s tanezumab and Johnson & Johnson/Takeda’s fulranumab, beginning in 2016.
Tanezumab and fulranumab to account for 19% of total pain market
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze